AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03875625 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietitian led life style modification intervention
Description: Intensive 6 months life style changes supervised by diatitians.
Study NCT03875625 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional care (control)
Description: receive routine care
Study NCT04382924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP-120 (Ifenprodil)
Description: Ifenprodil, 20 mg TID Ifenprodil, 40 mg TID
Study NCT04469647 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serology Test
Description: Participants will be seen at T0 (baseline),T2 (2 months after T0), and T4 (2 months after T2).~at every visit, participants will be asked to complete a general surveillance survey and a blood sample will be taken for the serology test.
Study NCT03434392 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Quantitative Sensory Test 1
Description: Subject will give pain rating (on Visual Analogue Scale (VAS) 0-10) of single as well as multiple stimulation with round-tip non-invasive pin-prick device. Difference is recorded as Temporal Summation Score.
Study NCT02401542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study NCT02401542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02520271 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Activation
Description: BA consists of at least 4 intervention sessions with a focused, active working style by the therapist. The therapy initiation includes a focused interview targeting at determining 1-2 main problems, on which the therapy will be focused. Specific therapeutic methods for BA include the use ABC analysis, targeting at hitting the negative consequences of current problematic behavior and motivating for change. Further, recognizing the obstacles for change (TRAP) is the next method to be used. The therapist encourages the client for active behavioral monitoring through assigned homework during the therapy process. The final step and method used is strengthening the gained change (ACTION).
Study NCT03434392 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Quantitative Sensory Test 2
Description: Subject will state when they first detect pain and pain detection threshold in response to pressure administration with pressure algometer. Pressure threshold recorded in kilopascals(kP). Stimulation will be repeated in pancreatic and control dermatomes. Subject will then state pain tolerance threshold at same locations. Sensitization will be characterized by ratio of pancreatic vs. control dermatome scores.
Study NCT02520271 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interview
Description: Motivational interview (MI) is a therapeutic intervention that focuses on resolving client ambivalence towards changing problematic behavior. MI involves a client-centered approach that encourages the client to develop his or her own motivation. The therapeutic alliance in MI is predominantly a partnership, rather than an expert/client dynamic.~MI has been studied primarily in addiction problems, but there are numerous reports of its efficacy in several chronic somatic conditions, and lifestyle problems.
Study NCT01787825 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PillCam SB2 capsule
Description: Capsule Endoscopy system
Study NCT01787825 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CapsoCam SV-1
Description: Capsule endoscopy
Study NCT03434392 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Quantitative Sensory Test 3
Description: Subject will apply dominant hand to ice-chilled water bath (36F) for up to 2 minutes. Pain score (VAS 0-10) will be assessed each 10 seconds. Pain tolerance threshold (in kP) will be assessed with algometer on non-dominant thigh before and after water bath to determine change in threshold. Difference in pain tolerance recorded as Conditioned Pain Modulation Score.
Study NCT01242202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: oral
Study NCT01242202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha glucosidase inhibitor
Description: oral
Study NCT04512534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody+ HDAC inhibitor
Description: Patients receive anti-PD-1 antibody Sintilimab+ HDAC inhibitor Chidamide three weeks for a cycle, detailed as follows:~* Anti-PD-1 antibody (Sintilimab): Fixed dose of 200 mg every 3 weeks, intravenous drip (without pretreatment), infusion time: 30 minutes (no less than 20 mins, no more than 60 mins), the maximum treatment period is 2 years (up to 35 doses), complete remission（CR）patients confirmed by imaging assessment can be considered off anti-PD-1 treatment after 12 treatment cycles.~* Chidamide: Chidamide is administered orally at a dose of 30mg (initial dose). It is recommended to be administered within 0.5h after a meal with a fixed time. Chidamide will be given until disease progression or intolerant toxicity. The maximum treatment is 2 years. If chidamide therapy requires to be continued over 2 years due to clinical benefit, the prescription/decision should be made after discussion with the principal investigator.
Study NCT00680901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 5 pills at 250mg each once daily
Study NCT00680901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 pills once daily
Study NCT00680901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1700mg/m2/day in two daily doses
Study NCT00680901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: 1700mg/m2/day in two daily doses
Study NCT00680901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m2 on day 1
Study NCT00680901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin
Description: 130mg/m2 on day 1
Study NCT04058652 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical nerve stimulation (TENS) unit
Description: The transcutaneous electrical nerve stimulation (TENS) unit is a noninvasive, inexpensive, battery-operated device that was originally designed to provide modulation of the afferent nervous system to relieve pain. By providing alternating current through cutaneous electrodes, TENS activates large-diameter afferent fibers of the nervous system (A-delta, A-beta, C fibers), whose ascending signals are subsequently relayed to the central nervous system.
Study NCT01864109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT01864109 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Study NCT01864109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Study NCT01864109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Study NCT01864109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study NCT01864109 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Study NCT01864109 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy*
Description: If local control includes RT, RT should be given concurrently with chemotherapy cycles
Study NCT01864109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study NCT04700995 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NiTi instruments
Description: Root canal filling removal
Study NCT04306900 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TTX-030, budigalimab and mFOLFOX6
Description: Dose and schedule per protocol
Study NCT04306900 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TTX-030, budigalimab and docetaxel
Description: Dose and schedule per protocol
Study NCT04306900 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TTX-030 and mFOLFOX6
Description: Dose and schedule per protocol
Study NCT04306900 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TTX-030 and budigalimab
Description: Dose and schedule per protocol
Study NCT04306900 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TTX-030, budigalimab, nab-paclitaxel and gemcitabine
Description: Dose and schedule per protocol
Study NCT04306900 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TTX-030 and pembrolizumab
Description: Dose and schedule per protocol
Study NCT04306900 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TTX-030, nab-paclitaxel and gemcitabine
Description: Dose and schedule per protocol
Study NCT04306900 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Budigalimab and mFOLFOX6
Description: Dose and schedule per protocol
Study NCT01864109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study NCT01864109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Mesna 2,100 mg/m2 (or 70 mg/kg if \< 10 yrs of age) administered intravenously in concordance with institutional pediatric administration guidelines.
Study NCT01864109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Description: Dexrazoxane 375 mg/m2 intravenously over approximately 15-30 minutes and as clinically indicated. To be administered immediately prior to doxorubicin.
Study NCT01864109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF-to be administered after the completion of appropriate chemotherapy cycles as per institutional guidelines.
Study NCT00624611 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Residual pump blood management post aortic cannula removal
Description: Residual pump blood will be maximally hemoconcentrated by further ultrafiltation within the CPB machine. Resulting hematocrit will be approximately 0.4. The total residual pump blood volume, approximately 300ml, will be reinfused over one hour, beginning 15 minutes after removal of the aortic cross clamp. Additional protamine sulfate will be given every 30 minutes during the infusion, .03 mg/ml of residual pump blood. Procedures in this group do not deviate from current standard practice.
Study NCT00624611 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Residual pump blood management post aortic cannula removal
Description: All residual pump blood will be processed with a bedside red cell washing device (Cell Saver). The resulting total volume of concentrated red cells will be infused over one hour, beginning 15 minutes after removal of the aortic cross clamp. Administration of additional protamine is not required due to the low concentrations of heparin in the resulting product.
Study NCT03422328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: macitentan
Description: macitentan 10 mg, film-coated tablet, oral use
Study NCT02875405 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior left pericardiotomy
Description: Patient will receive a posterior left sided pericardiotomy. The incision will be made posterior to the phrenic nerve and run from the inferior left pulmonary vein to the diaphragm.
Study NCT02694094 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Modified Atkins or Ketogenic Diet
Description: Biochemical and vascular parameters will be compared from adults who have been on ketogenic diet therapy for > 12 months to adults naive to ketogenic diet therapy. In addition, adults naive to diet therapy who subsequently begin diet therapy will have these same parameters followed over time.
Study NCT02784210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 3 days of corticosteroids (intravenous methylprednisolone at 1000 mg/day
Study NCT02784210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 3 days of corticosteroids (oral prednisone at 1250 mg/day
Study NCT01973322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: arm 1: DC Vaccine + RT
Description: three daily doses of 8 Gy up to 12 Gy delivered to one non-index metastatic field between vaccine doses 1 and 2 (optional to one additional field between vaccine doses 7 and 8) utilizing IMRT-IMAT techniques
Study NCT01973322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: arm 2: DC Vaccine + IFN-alfa
Description: daily 3 MU subcutaneous IFN-alfa for 7 days before leukapheresis (day -15 to -9, and for 7 days before any other additional leukapheresis)
Study NCT01973322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: arm 3: both arm 1 and 2 + RT
Description: both 1 and 2 external immunostimulant conditions (Intradermal Autologous Dendritic Cell Vaccine + 3 single boosts of RT + IFN-alfa, 3 MU daily for 7 days before leukapheresis)
Study NCT01973322 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: arm 4: DC Vaccine
Description: neither 1 or 2 external immunostimulant conditions (only Intradermal Autologous Dendritic Cell Vaccine)
Study NCT03262779 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: combination nivolumab and ipilimumab
Description: Combination therapy with nivolumab 3 mg/kg administered intravenously (IV) every 2 weeks, with ipilimumab 1 mg/kg administered IV every 6 weeks.
Study NCT02799186 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood sample for genetic analysis
Study NCT01059643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2523355
Description: Dose determined by participant body surface area: 5 milligrams/square meter(mg/m²) or 6 mg/m², administered intravenously as a 1-hour infusion on Days 1, 2 and 3 of a 21 day cycle; for up to 2 cycles (4 cycles for prostate cancer patients). Additional cycles administered based on patient response assessment.
Study NCT01059643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: 6 milligrams (mg), administered subcutaneously approximately 24 hours after third dose of LY2523355 on Day 4 of each 21-day cycle, for up to 2 cycles of LY2523355 administration (4 cycles for prostate cancer patients). Additional cycles of LY2523355 administered based on patient response assessment.
Study NCT03860961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03860961 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03860961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survivorship Care Plan (SCP)
Description: Given survivorship care plan
Study NCT03860961 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survivorship Care Plan (SCP)
Description: Given survivorship care plan
Study NCT03860961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment Plan
Description: Given treatment plan
Study NCT03737201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ozone
Description: In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as ozone.
Study NCT03737201 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine digluconate
Description: In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as chlorhexidine digluconate.
Study NCT03737201 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: without any cavity disinfectant
Study NCT03295903 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol supplement
Description: Subjects will be administered in a double-blinded, randomized and cross-over design
Study NCT03295903 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cannabidiol supplement
Description: Subjects will be administered in a double-blinded, randomized and cross-over design
Study NCT03978910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: measurements of the accuracy of the reaching movements
Description: Euclidian distance between final position and target
Study NCT02835872 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: dietary fiber
Description: Fiber containing drink mixes and crackers to be consumed with meals (1g fiber/serving) three times per day for a total of 3 g fiber.
Study NCT02835872 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dietary fiber
Description: Fiber containing drink mixes and crackers to be consumed with meals (1g fiber/serving) three times per day for a total of 3 g fiber.
Study NCT01406704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: Rosiglitazone (8 mg/day)
Study NCT01406704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha-lipoic acid
Description: alpha-lipoic acid (1800 mg/day)
Study NCT01406704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone/alpha-lipoic acid
Description: combination of Rosiglitazone (8 mg/day) and Thioctic acid (1800 mg/day)
Study NCT02437825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: octreotide
Description: Octreotide has been in clinical use for thirty years and approved for use in Israel in acromegaly and functional gastroenteropancreatic tumours. It is currently being used extensively in surgical patients to prevent pancreatic fistulae1, and in lymphorrhea (both lymphatic malformations and leaks from the thoracic duct)
Study NCT02437825 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo ( saline) act as comperator in this study.
Study NCT01390714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E3710
Description: Arm A:~1. E3710 40 mg→RPZ 10 mg→E3710 20 mg~2. RPZ 10 mg→E3710 20 mg→E3710 40 mg~3. E3710 20 mg→E3710 40 mg→RPZ 10 mg~Crossover study of E3710 40 mg, E3710 20 mg, and PRZ 10 mg, once daily, for 5 days, oral administration.
Study NCT01390714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E3710
Description: Arm B:~1. E3710 40 mg→E3710 80 mg→EPZ 40 mg~2. E3710 80 mg→EPZ 40 mg →E3710 40 mg~3. EPZ 40 mg→E3710 40 mg→E3710 80 mg~Crossover study of E3710 40 mg, E3710 80 mg, and EPZ 40 mg, once daily, for 5 days, oral administration.
Study NCT03997708 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Med-LFD
Description: All participants of this group at phase 1 (elimination phase), will initially follow the Med- LFD (2-6 weeks). At phase 2 (reintroduction phase), patients will gradually reintroduce foods rich in FODMAPs (6-8 weeks) and test their tolerance. At phase 3 (maintenance phase), following the reintroduction of foods rich in FODMAPs, patients will follow an individualized diet based on their personal tolerance (a combination of high and low FODMAPs).
Study NCT03997708 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Guidelines of the British National Institute for Health and Care Excellence (NICE) Managing IBS
Description: All participants of this group will be informed to follow a diet based on the nutritional guidelines of the British National Institute for Health and Care Excellence (NICE) for Managing IBS for 4 weeks.
Study NCT01107249 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Boston Scientific Ultraflex or Wallstent stents
Description: Stent used to maintain luminal patency in esophageal strictures and occlude esophageal fistulas to reduce gastric leaks, perforations and/or fistulas.
Study NCT01785771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITCA 650 (exenatide in DUROS)
Study NCT00577018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: 4 mg o.d.
Study NCT00577018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: 1 mg o.d. for 2 days, 2 mg o.d. for 2 days and 4 mg o.d. thereafter
Study NCT00721708 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pure carnosine
Description: one time dose of pure carnosine (450 mg)
Study NCT00721708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beef
Description: one time dose, 150 g of beef
Study NCT00721708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chicken
Description: One time dose, 150g of chicken breast
Study NCT03104322 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: patientMpower platform
Description: electronic health journal for patient to record compliance, spirometry, impact on daily life and symptoms
Study NCT03104322 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: usual care
Description: usual care
Study NCT03755414 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation
Description: Standard of care
Study NCT03755414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Itacitinib may be taken without regard to food.
Study NCT03755414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT)
Description: * Screening, day 14, day 28, day 42, day 74, day 100, taper period, and follow-up (pilot study)~* Screening, day 14, day 28, day 42, day 74, day 100, day 180, taper period, and follow-up period (expansion study)